• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why BioRestorative Therapies Stock Is Moving Higher Thursday

    6/13/24 11:52:46 AM ET
    $BRTX
    $CADL
    Managed Health Care
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BRTX alert in real time by email

    BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares are trading higher Thursday after the company said it has engaged in licensing discussions with a undisclosed commercial regenerative medicine company.

    What Happened: BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with an regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property.

    Research conducted in collaboration with the University of Utah School of Medicine has demonstrated that certain stem cells with brown adipogenic potential could represent a new way of treating obesity and related metabolic disorders.

    Currently, there is no guarantee that a license agreement will be made between the two companies.

    Related Link: Candel Therapeutics’ (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

    BRTX Price Action: At the time of writing, BioRestorative shares are trading 29% higher at $1.75 per data from Benzinga Pro.

    Image: Image via Shutterstock

    Get the next $BRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRTX
    $CADL

    CompanyDatePrice TargetRatingAnalyst
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    Candel Therapeutics Inc.
    $CADL
    2/20/2025$25.00Buy
    Citigroup
    Candel Therapeutics Inc.
    $CADL
    2/19/2025$20.00Buy
    Canaccord Genuity
    Candel Therapeutics Inc.
    $CADL
    2/7/2025$15.00Buy
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    12/2/2022$11.00Buy
    H.C. Wainwright
    BioRestorative Therapies Inc.
    $BRTX
    12/1/2021$37.00Buy
    Roth Capital
    More analyst ratings

    $BRTX
    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:04:50 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Nichols William Garrett

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:03:33 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Schoch Charles

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:02:42 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRTX
    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioRestorative Announces Closing of $5.0 Million Public Offering

    MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.35 per share, are immediately exercisable and will expire five years from

    2/13/26 8:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Announces Pricing of $5.0 Million Public Offering

    MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the pricing of a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $0.35 per share and will be exercisable immediately upon issuance and will expire five years f

    2/11/26 10:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

    NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel's Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts. Dr. Barone will share insights from Candel's HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discu

    2/11/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRTX
    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    12/18/24 4:11:47 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silva Francisco bought $10,229 worth of shares (8,308 units at $1.23), increasing direct ownership by 6% to 155,759 units (SEC Form 4)

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    4/10/24 5:16:36 PM ET
    $BRTX
    Managed Health Care
    Health Care

    Broadrick Dale bought $206,023 worth of shares (160,000 units at $1.29) (SEC Form 4)

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    2/12/24 9:26:34 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00

    9/3/25 8:04:26 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Candel Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Candel Therapeutics with a rating of Buy and set a new price target of $23.00

    6/30/25 7:59:11 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRTX
    $CADL
    SEC Filings

    View All

    SEC Form 424B4 filed by BioRestorative Therapies Inc.

    424B4 - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/13/26 9:48:15 AM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form EFFECT filed by BioRestorative Therapies Inc.

    EFFECT - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/12/26 12:15:31 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Amendment: SEC Form S-1/A filed by BioRestorative Therapies Inc.

    S-1/A - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/10/26 5:20:59 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $CADL
    Leadership Updates

    Live Leadership Updates

    View All

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRTX
    $CADL
    Financials

    Live finance-specific insights

    View All

    BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

    MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Third Quarter 2025 Results Conference Call Details: Date: Wednesday, November 12, 2025Time: 4:30 p.m. ETDomestic: 1-888-506-0062International: 1-973-528-0011Access Code: 464585 The call will also b

    11/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

    MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, Chief Executive Officer of BioRestorative. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and see many potential value

    8/12/25 4:05:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

    MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2025 Results Conference Call Details: Date:Tuesday, August 12, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:436077 The call will al

    8/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    3/6/24 4:34:22 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    2/15/24 4:43:54 PM ET
    $BRTX
    Managed Health Care
    Health Care